Mood Stabilizer Adverse Events · Section 4 · Chapter 13 · Lamotrigine
Starting and Restarting Lamotrigine: Titration, Valproate and Missed Doses
With lamotrigine, the titration is the safety measure. Starting too fast, forgetting valproate, or restarting at the old dose after a break each raise the risk of the rash covered in Chapter 12. This chapter is about choosing the right schedule, adjusting it when other medicines start or stop, and what to do when a patient has missed doses or wants to restart.
The 30-second version
- Why the titration is the safety measure. Exceeding the starting dose or the rate of increase is named in the boxed warning as a risk factor for serious rash. The slow start is what makes lamotrigine safe to use, and it is why lamotrigine is not a drug for a patient who needs a rapid response.
- Choosing the column. The label's bipolar schedule has three columns: taking valproate, taking an enzyme inducer and not valproate, or neither. Pick the column from the current medicine list, follow it to the target, and do not go above 200 mg/day without a reason.
- Valproate, in either direction. Valproate more than doubles lamotrigine concentrations and is a risk factor for serious rash. Starting lamotrigine on valproate uses the slowest column. Adding valproate means reducing lamotrigine. Stopping valproate means doubling lamotrigine over two weeks.
- Contraceptives and other hormones. Estrogen-containing contraceptives lower lamotrigine levels. They do not change the starting schedule, but starting or stopping one changes the maintenance dose. Progestin-only pills do not. Expect levels to rise in the pill-free week, and do not adjust for that week alone.
- Missed doses and restarting after a gap. After more than five half-lives off lamotrigine, the label says restart from the beginning of the schedule. On average that is about five days on lamotrigine alone, about two weeks with valproate, and under three days with an inducer, but individuals vary widely. When the gap is long or unclear, start again from week 1 of the right column.
- Restarting after a rash. The label lists rash among the hypersensitivity reactions that contraindicate lamotrigine. After SJS, TEN or DRESS, lamotrigine is not restarted. After a rash judged benign, a restart is a specialist decision against the label's caution, with the full slow schedule from the beginning.
At the bedside: starting, restarting or a missed dose
About 2 min to read · the detailed chapter follows below
Do now
- Choose the column: valproate, an inducer such as carbamazepine, or neither.
- Prescribe the label's schedule exactly, and use a starter kit where available.
- Tell the patient what a rash, mouth sores or fever mean, and to stop and call.
- Recheck the dose whenever valproate, an inducer or an estrogen-containing contraceptive starts or stops.
- Before any restart, ask why lamotrigine stopped and when the last dose was.
Do not
- Exceed the starting dose or the escalation, even when the patient is desperate to feel better.
- Restart at the previous dose after a long gap.
- Restart lamotrigine after SJS, TEN or DRESS.
- Add valproate without reducing lamotrigine.
- Adjust the dose for the pill-free week alone.
- Use a blood level to set the dose; no therapeutic range is established.
Five questions to ask
- Is the patient taking valproate? It sets the slowest column and halves the target.
- Carbamazepine, phenytoin, phenobarbital, primidone, rifampin, or lopinavir/ritonavir? These put the patient in the inducer column.
- An estrogen-containing contraceptive or HRT, and is it starting or stopping? It changes the maintenance dose, not the start.
- If restarting: when was the last dose, and why did it stop? The gap decides where to restart; the reason decides whether to.
- Has lamotrigine, or any anticonvulsant, ever caused a rash, mouth sores or fever? See Chapter 12 before going further.
Do not restart if
- It stopped because of SJS, TEN or DRESS
- It stopped because of a rash with mouth sores, blisters, fever or swollen glands
- Then: record lamotrigine as contraindicated and choose another treatment
Specialist decision first if
- It stopped because of a rash judged benign
- The label advises against restarting unless the benefits clearly outweigh the risks; see Chapter 12
Restart from week 1 if
The gap is longer than five half-lives (on average about five days alone, two weeks with valproate, under three days with an inducer), or you cannot tell how long it was: use week 1 of the column that matches the patient's current medicines. After a shorter gap the label leaves it to judgement; the longer the gap, the stronger the case for starting again.
Prescriber-side triage for a lamotrigine restart. Our synthesis of the US label's contraindication, boxed warning and restarting advice, not a validated instrument [1][2]. It matches Chapter 12: no restart after SJS, TEN or DRESS.
Why it goes wrong
- Valproate is forgotten, so the patient gets the faster column.
- A patient restarts the old tablets at home after a break.
- The starting dose is raised early because the patient feels no better.
- An estrogen pill is started or stopped and nobody adjusts lamotrigine.
- The pharmacy dispenses the wrong drug or formulation; the names are easily confused.
Write on the prescription and in the notes
- The column used, and why: valproate, inducer, or neither
- Each step with its dates, to the target dose
- That rash, mouth sores or fever mean stop and call
- What to do about a missed dose, and when to call instead
- Any rash history, and its type
Look up a restart
Tap why lamotrigine stopped. The gap decides where to restart; the reason decides whether to.
Serious rash or reaction
Rash judged benign
Never a rash
Stopped because of SJS, TEN or DRESS, or a rash with mouth sores, blisters, fever or swollen glands
Do not restartAfter Stevens-Johnson syndrome, toxic epidermal necrolysis or DRESS, there is no restart.
What to do
- Record lamotrigine as contraindicated
- Choose another treatment
- The same applies after a rash that came with mouth sores, blistering, fever or swollen glands, even if it was never formally diagnosed
Why
- Lamotrigine is contraindicated in patients who have shown hypersensitivity to it, giving rash, angioedema, acute urticaria, extensive pruritus and mucosal ulceration as examples [1][2]
- None of the sources cited here or in Chapter 12 describes a safe way back
Stopped because of a rash judged benign
Specialist decision firstThe label recommends that lamotrigine not be restarted in patients who stopped it because of a rash unless the potential benefits clearly outweigh the risks [1][2].
If a restart is chosen
- A deliberate, documented decision, made with the patient once the rash has fully settled
- Starting from the beginning of the schedule and never faster than the label's column
- Confirming the first rash had no features of a severe rash is critical [5]
The evidence
- A prospective case series of 27 patients rechallenged after a rash found that five stopped again because of rash or inflammation and none developed SJS or TEN [4]
- A systematic review of 106 published rechallenges found most successful, while noting that only three of the first rashes had been confirmed by a dermatologist [5]
- Both used schedules slower than usual
Never a rash
Restart from week 1If the patient has been off lamotrigine for more than five half-lives, the initial dosing recommendations should be followed [1][2].
What to do
- Restart from week 1 of the column that matches the patient's current medicines, not the medicines they were on before
- The label recommends starter kits for restarting as well as starting [1]
- After a shorter gap the label leaves it to judgement; the longer the gap, the stronger the case for starting again
Five half-lives, on average
- About five days on lamotrigine alone
- About two weeks with valproate
- Under three days with an inducer
- The ranges around each average are wide
Why the titration is the safety measure
Exceeding the starting dose or the rate of increase is named in the boxed warning as a risk factor for serious rash. The slow start is what makes lamotrigine safe to use, and it is why lamotrigine is not a drug for a patient who needs a rapid response.
Two practical tools help. The label recommends starter kits, which provide doses consistent with the titration schedule for the first five weeks according to the patient's other medicines, for appropriate patients who are starting or restarting lamotrigine, and says they are intended to help reduce the potential for rash [1]. And the label warns that medication errors have occurred: the names can be confused with other commonly used medicines, errors occur between formulations, and patients should be advised to check their tablets each time they collect a prescription [1].
The detail: the boxed warning, and the price in time
The boxed warning lists four factors that may increase the risk or severity of lamotrigine rash, and two of them are in the prescriber's hands: exceeding the recommended initial dose, and exceeding the recommended dose escalation [1][2]. The bipolar dosing section repeats the instruction directly: to avoid an increased risk of rash, the recommended initial dose and subsequent dose escalations should not be exceeded [1]. CANMAT adds that with a low starting dose and gradual titration, the risk of serious rash may be much lower than the overall figures suggest [3].
The price is time. CANMAT notes that lamotrigine needs a slower titration because of the risk of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis, and so is not ideal for patients who need a rapid response [3]. That is worth saying to the patient at the start. A patient who understands why the first weeks feel slow is less likely to double up.
Choosing the column
The label's bipolar schedule has three columns: taking valproate, taking an enzyme inducer and not valproate, or neither. Pick the column from the current medicine list, follow it to the target, and do not go above 200 mg/day without a reason.
The label's escalation regimen for adults with bipolar disorder is set by the patient's other medicines [1][2]. Valproate inhibits glucuronidation and decreases the clearance of lamotrigine, so its column is the slowest. Carbamazepine, phenytoin, phenobarbital and primidone increase clearance, so their column is the fastest. The label adds that rifampin and lopinavir/ritonavir should be treated like those inducers, while estrogen-containing contraceptives and atazanavir/ritonavir do not change the escalation and are handled separately [1][2].
| Week | Taking valproate | Taking neither valproate nor an inducer | Taking an inducer, not valproate |
|---|---|---|---|
| Weeks 1 and 2 | 25 mg every other day | 25 mg daily | 50 mg daily |
| Weeks 3 and 4 | 25 mg daily | 50 mg daily | 100 mg daily, divided |
| Week 5 | 50 mg daily | 100 mg daily | 200 mg daily, divided |
| Week 6 | 100 mg daily | 200 mg daily | 300 mg daily, divided |
| Week 7 | 100 mg daily | 200 mg daily | Up to 400 mg daily, divided |
The US label's escalation regimen for adults with bipolar disorder (Table 5), reproduced from the label [1][2]. "Inducer" means carbamazepine, phenytoin, phenobarbital or primidone, and, per the label, rifampin or lopinavir/ritonavir. Check the current label before prescribing.
The column is not fixed for life. The label says that if other medicines are introduced later, the lamotrigine dose may need adjusting, and in particular that introducing valproate requires a reduction [1]. Recording the column, and the reason for it, on the prescription is what makes the next prescriber notice when it changes.
The detail: the target dose, levels and review
The target dose is 200 mg/day: 100 mg/day with valproate, and 400 mg/day with an inducer and no valproate [1]. In the bipolar trials, doses up to 400 mg/day as monotherapy were evaluated, no additional benefit was seen at 400 mg/day over 200 mg/day, and the label therefore does not recommend doses above 200 mg/day [1]. The label also says no therapeutic plasma concentration range has been established, so the dose is set by response, not by a level [1], and that patients on lamotrigine for more than 16 weeks should be reassessed periodically for the need for maintenance treatment [1].
Valproate, in either direction
Valproate more than doubles lamotrigine concentrations and is a risk factor for serious rash. Starting lamotrigine on valproate uses the slowest column. Adding valproate means reducing lamotrigine. Stopping valproate means doubling lamotrigine over two weeks.
Valproate increases lamotrigine concentrations more than two-fold, according to the label's interaction section [1], and coadministration with valproate is one of the boxed warning's risk factors for serious rash [1][2]. The combination is common in bipolar disorder, and it is the one most often mishandled.
Starting lamotrigine in a patient already taking valproate means the valproate column: 25 mg every other day for the first two weeks, rising to a target of 100 mg/day [1][2]. Starting valproate in a patient already taking lamotrigine is the riskier direction, because the existing dose suddenly behaves like a much larger one. The label says the introduction of valproate requires a reduction in the lamotrigine dose, but its bipolar section does not state the size of the reduction; it refers to the interaction and pharmacokinetic sections [1]. Plan that change with the label in hand, before the first dose of valproate.
Stopping valproate works the other way. The label says the lamotrigine dose should be doubled over a two-week period in equal weekly increments [1]. Its worked example starts from 100 mg/day: 150 mg/day in the first week after valproate stops, then 200 mg/day from the second week onwards [1]. Stopping an inducer is the mirror image: keep the dose the same for the first week, then halve it over two weeks in equal weekly decrements, so 400 mg/day becomes 300 mg/day and then 200 mg/day [1]. Stopping any other psychotropic needs no change to lamotrigine [1].
Three changes that move the dose (figure)
Figure 1. Three changes that move the lamotrigine dose, and what the US label says to do. The valproate and inducer figures are the label's worked examples (Table 6); the contraceptive instruction is from its general dosing section [1]. Not a substitute for the full label.
Contraceptives and other hormones
Estrogen-containing contraceptives lower lamotrigine levels. They do not change the starting schedule, but starting or stopping one changes the maintenance dose. Progestin-only pills do not. Expect levels to rise in the pill-free week, and do not adjust for that week alone.
Estrogen-containing oral contraceptives increase the clearance of lamotrigine, but the label says no change to the starting escalation is needed on that account alone: the escalation follows the patient's other medicines as usual [1][2]. The maintenance dose is different. In women not taking an inducer, the label says the maintenance dose will in most cases need to be increased by as much as two-fold over the usual target to keep a consistent level [1][2]. This is why the label's 200 mg/day ceiling for bipolar disorder and its contraceptive instruction can both be true: the ceiling describes the usual target, and the contraceptive changes what dose achieves it.
Starting a contraceptive in a woman already stable on lamotrigine calls for the same increase, beginning when the contraceptive starts and rising, according to clinical response, no faster than 50 to 100 mg/day each week [1]. Stopping the contraceptive is the reverse: the maintenance dose will in most cases need to fall by as much as 50%, with the decrease not exceeding 25% of the total daily dose per week over two weeks, unless response or levels indicate otherwise [1]. In a woman also taking an inducer, neither change is needed [1].
The pill-free week
The pill-free week catches people out. During the week of inactive tablets, lamotrigine levels are expected to rise, as much as doubling by the end of the week, and adverse effects such as dizziness, unsteadiness and double vision can occur [1]. The rise is greater if the dose has just been increased [1]. If symptoms consistently occur in that week, the label says the overall maintenance dose may need adjusting; adjustments limited to the pill-free week are not recommended [1].
The detail: progestins and hormone replacement therapy
Other hormones are less certain. The label reports that ethinyl estradiol, not progestins, increased lamotrigine clearance, and that progestin-only pills had no effect on lamotrigine levels, so adjustment is unlikely to be needed with progestins alone [1]. Other estrogen-containing therapies, such as hormone replacement therapy, have not been systematically studied and may interfere with lamotrigine, so the label asks for close clinical monitoring with dose adjustment if needed [1].
Missed doses and restarting after a gap
After more than five half-lives off lamotrigine, the label says restart from the beginning of the schedule. On average that is about five days on lamotrigine alone, about two weeks with valproate, and under three days with an inducer, but individuals vary widely. When the gap is long or unclear, start again from week 1 of the right column.
In practice that gives a simple rule for the long gap and a judgement for the short one. When the gap is clearly long, or nobody can say how long it was, restart from week 1 of the column that matches the patient's current medicines, not the medicines they were on before; the label recommends starter kits for restarting as well as starting [1]. When only a dose or two has been missed, the label gives no specific instruction beyond its principle that the longer the gap, the stronger the case for starting again [1]. A missed-dose plan agreed in advance, and written down, is better than a patient deciding alone.
Two other things change at a restart. The patient may have started or stopped valproate, an inducer or a contraceptive while off lamotrigine, which moves them into a different column or changes the eventual maintenance dose. And the reason it stopped matters more than the gap: if it stopped because of a rash, the next section applies before anything else.
The detail: the label's restarting advice and the half-life numbers
The label's restarting advice has three parts [1][2]. If a decision is made to restart, the need to restart with the initial dosing should be assessed. The greater the interval since the previous dose, the greater the consideration that should be given to restarting with the initial dosing. And if the patient has been off lamotrigine for more than five half-lives, the initial dosing recommendations should be followed [1][2]. The label adds that the half-life is affected by other medicines [1]: valproate decreases the clearance of lamotrigine and inducers increase it [1], so the same calendar gap counts for more in a patient taking an inducer than in one taking valproate.
The pharmacokinetic table in the FDA-approved labelling puts numbers on this. In healthy volunteers on repeated dosing, the mean half-life was about 25 hours on lamotrigine alone and about 70 hours with valproate; in patients with epilepsy taking enzyme-inducing anticonvulsants it was about 13 hours [6]. On those averages, five half-lives is roughly five days alone, two weeks with valproate and under three days with an inducer. The ranges around each average are wide, so these are guides for the typical patient, not guarantees for the one in front of you.
Restarting after a rash
The label lists rash among the hypersensitivity reactions that contraindicate lamotrigine. After SJS, TEN or DRESS, lamotrigine is not restarted. After a rash judged benign, a restart is a specialist decision against the label's caution, with the full slow schedule from the beginning.
Chapter 12 deals with rash in detail; this section sets out where it meets the restart decision, and the two chapters say the same thing. The label's contraindications section says lamotrigine is contraindicated in patients who have shown hypersensitivity to it, giving rash, angioedema, acute urticaria, extensive pruritus and mucosal ulceration as examples [1][2]. Its dosing section recommends that lamotrigine not be restarted in patients who stopped it because of a rash unless the potential benefits clearly outweigh the risks [1][2].
After SJS, TEN or DRESS
After Stevens-Johnson syndrome, toxic epidermal necrolysis or DRESS, there is no restart. These are the hypersensitivity reactions the contraindication describes, and none of the sources cited here or in Chapter 12 describes a safe way back. The same applies after a rash that came with mouth sores, blistering, fever or swollen glands, even if it was never formally diagnosed. Record lamotrigine as contraindicated and choose another treatment.
The detail: rechallenge after a rash judged benign
After a rash judged benign, the evidence allows a restart in selected patients, but not a casual one. A prospective case series of 27 patients rechallenged after a rash found that five stopped again because of rash or inflammation and none developed SJS or TEN [4], and a systematic review of 106 published rechallenges found most successful, while noting that only three of the first rashes had been confirmed by a dermatologist [5]. Both used schedules slower than usual, and the review's authors concluded that confirming the first rash had no features of a severe rash is critical [5]. A restart in this situation is a deliberate, documented decision, made with the patient once the rash has fully settled, starting from the beginning of the schedule and never faster than the label's column.
Clinical pearls
- With lamotrigine, the titration is the safety measure.Never exceed the starting dose or the escalation.
- Pick the column from today's medicine list: valproate, inducer, or neither.
- Valproate halves the target and slows the start.Forgetting it is the classic error.
- Adding valproate means cutting lamotrigine first.Stopping valproate means doubling it over two weeks.
- Estrogen pills do not change the start, but may raise the maintenance dose up to two-fold.Progestin-only pills do not.
- Expect symptoms in the pill-free week; adjust the overall dose, not that week.
- Off lamotrigine for a long or unknown time: start again from week 1.
- Always ask why it stopped.After SJS, TEN or DRESS, lamotrigine does not come back.
- No therapeutic range is established.Dose by response, not by level.
- Write the column, the steps and the missed-dose plan on the prescription.
Patient script & EMR note
Counselling script: restarting after a break
"Thanks for checking before you took it. Please don't restart at 200 mg. When lamotrigine has been stopped for a while, the instructions that come with it say to start again from the beginning, because going straight back to the full dose raises the risk of a serious skin reaction.
So we'll begin with one low dose a day for two weeks, then a little more every couple of weeks, back up to where you were. I'll write each step down with the dates. I know that's slower than you'd like when your mood is low, and I'll keep in touch while we build up.
Two things to watch for. If you get a rash, sores in your mouth, sore eyes or a fever, stop the tablets and call me the same day. We'll set your final dose by how you feel. The combined pill can mean some people need more than the usual dose, so if you start or stop it, tell me.
If you ever miss doses again, call before restarting. That's what this plan is for."
EMR note: copy, paste and edit
LAMOTRIGINE – START / RESTART PLAN Indication: [ ] Start or restart: [ ] If restart: last dose 2026 Gap: [ ] Reason stopped: [ ] Rash history on lamotrigine or other anticonvulsant: [none / type] (SJS, TEN, DRESS, or rash with mucosal sores, blisters, fever or swollen glands = do not restart; record as contraindicated) Current medicines: Valproate [Y/N] Inducer (carbamazepine, phenytoin, phenobarbital, primidone, rifampin, lopinavir/ritonavir) [Y/N] Estrogen-containing contraceptive / HRT [Y/N] Progestin-only [Y/N] Column used (label Table 5): [valproate / neither / inducer] Schedule with dates: Weeks 1-2 [ ] Weeks 3-4 [ ] Week 5 [ ] Week 6 [ ] Week 7 [ ] Target: [ ] Starter kit: [Y/N] Patient told: stop and call same day for rash, mouth sores, sore eyes or fever [Y/N] Missed-dose plan: [ ] Dose review if valproate / inducer / estrogen starts or stops [Y/N] Clinician: [ ] Date/time: [ ]
Case: Tuesday, 11:00 am
A 34-year-old woman with bipolar II disorder has been well for a year on lamotrigine 200 mg daily, with no other psychotropic. She also takes a combined estrogen-containing contraceptive pill, which she started before lamotrigine.
Three weeks ago she ran out of lamotrigine while travelling and did not refill it. Her mood has dipped, and she has a full bottle at home. She messages the clinic: "Can I just go back to my 200 mg tonight?" She has never had a rash on lamotrigine.
By the end of this chapter you should be able to say whether she can restart, at what dose, and what her contraceptive means for where the dose ends up.
Case resolution
She cannot go back to 200 mg tonight. Three weeks off is far longer than five half-lives on lamotrigine alone, which averages about five days, so the label's advice is clear: start again from the beginning. She has never had a rash, so a restart is reasonable, from the beginning.
She takes no valproate and no inducer, so she uses the middle column: 25 mg daily for two weeks, then 50 mg daily for two weeks, then 100 mg, then 200 mg. Her combined pill does not change that schedule.
It does change where she may end up. Because she takes an estrogen-containing pill and no inducer, the label says her maintenance dose may in most cases need to be up to twice the usual target to keep a consistent level, guided by her response. The clinician also explains the pill-free week, and writes down what she should do if she misses a dose again.
Her notes record the column, the reason, each step with dates, and "no rash history". She is told that a rash, mouth sores or fever mean stopping and calling the same day.
Why every restart is a new start
Lamotrigine is the mood stabilizer patients most often stop on their own: they run out, travel, feel well, or forget. They also restart on their own, usually at the dose they were on. That single decision, taken at home without a prescriber, recreates the conditions the boxed warning describes. The titration schedule is not a formality, and every restart is a new start until proven otherwise.
References (6)
- Lamictal (lamotrigine) tablets, tablets for oral suspension and orally disintegrating tablets [US prescribing information]. Boxed Warning, Dosage and Administration (2.1 general dosing considerations; 2.4 bipolar disorder, Tables 5 and 6), Contraindications (4), Warnings and Precautions (5.8 medication errors; 5.9 concomitant use with oral contraceptives) and Drug Interactions (7). GlaxoSmithKline; revised October 2025. DailyMed setid d7e3572d-56fe-4727-2bb4-013ccca22678. Source type: US structured product label.
- Lamotrigine tablets [US prescribing information]. Boxed Warning, Dosage and Administration (2.1; 2.4 Table 5) and Contraindications (4). Aurobindo Pharma Limited; revised May 2026. DailyMed setid a9a4309e-fe43-4a26-a30f-c6577d650336. Source type: US structured product label from a different manufacturer.
- Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170. doi:10.1111/bdi.12609. p120 and Section 8.3.10 (pp145–146). Source type: clinical practice guideline.
- Aiken CB, Orr C. Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature. Psychiatry (Edgmont). 2010;7(5):27–32. Source type: prospective case series with literature review.
- Riva HR, Zheng S, Sohail N, Newman SA, Ortiz PE. Rechallenge of lamotrigine after rash: a systematic review. J Clin Psychiatry. 2026;87(1):25r15987. Source type: systematic review of published cases.
- Lamictal (lamotrigine) tablets and chewable dispersible tablets [US prescribing information]. Clinical Pharmacology, Table 1 (mean pharmacokinetic parameters). GlaxoSmithKline; FDA-approved labelling 20 June 2003 (NDA 20-241/S-017, NDA 20-764/S-011). accessdata.fda.gov. Source type: US product label (earlier revision, cited for the half-life table only).
Last reviewed October 2026. Part of the Psychiatry Education Forum Academy, Managing Mood Stabilizer Adverse Events · Section 4 · Chapter 13.
Managing Mood Stabilizer Adverse Events
The rest of the course applies the same rapid-decision format to the serious adverse effects of lithium, valproate, lamotrigine, carbamazepine and oxcarbazepine: the rash that has to stop lamotrigine, the rarer systemic reactions to lamotrigine, HLA testing and serious rash on carbamazepine, and more.
This chapter is educational material for licensed prescribers and prescribers in training. It is not a substitute for clinical judgement, local protocols or the current prescribing information; check lamotrigine doses against the current label before prescribing. A rash, mouth sores or fever on lamotrigine should be assessed the same day. Psychiatry Education Forum Academy is not a CME provider and this chapter does not carry CME credit.
Responses